2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Dermatologic
1
Conditions
Vomiting
39
Nausea
31
Neoplasms
10
Breast Neoplasms
10
Lymphoma
9
Multiple Myeloma
7
Ovarian Neoplasms
6
Lymphoma, Non-Hodgkin
6
Leukemia, Myeloid, Acute
6
Sezary Syndrome
4
Myeloproliferative Disorders
4
Leukemia
4
Carcinoma, Non-Small-Cell Lung
4
Pruritus
3
Primary Myelofibrosis
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pdgfra-Associated Chronic Eosinophilic Leukemia
3
Neoplasms, Plasma Cell
3
Myelodysplastic Syndromes
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Neutrophilic, Chronic
3
Leukemia, Myelomonocytic, Chronic
3
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Interventions
Sunitinib
145
Nivolumab
144
pembrolizumab
132
Sorafenib
84
Bevacizumab
77
Everolimus
74
cabozantinib
71
pazopanib
65
Axitinib
65
Ipilimumab
62
aldesleukin
52
Magnetic Resonance Spectroscopy
45
Cyclophosphamide
40
Interleukin-2
38
lenvatinib
37
Specimen Handling
36
Radiosurgery
36
Interferon-alpha
32
atezolizumab
30
temsirolimus
27
belzutifan
24
Gemcitabine
23
fludarabine phosphate
22
avelumab
22
Radiotherapy
19
Interferon alpha-2
19
Biopsy
18
fludarabine
17
durvalumab
17
Nephrectomy
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Aprepitant
×
Clear all
NCT01874119
2018-06-07
HDIL2/Emend
St. Louis University
Phase 2
Terminated
13 enrolled
7 charts